reports
- Jonathan Moreland
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Pl...
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement age...
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 ...
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety ...
ONEOK to Participate in Investor Conference
ONEOK to Participate in Investor Conference TULSA, Okla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- ONEOK, Inc. (NYSE: OKE) will participate in an investor conference this week and in a fireside chat session at 2:15 p.m. Eastern Time (1:15 p.m. Central Time) on Tuesday, Dec. 9. The session will be webcast live on ONEOK’s website at . The webcast will also be available for replay. ONEOK’s latest investor materials are available at . ------------------------------------------------------------------------------------------------------------------- At ONEOK (NYSE: OKE), we deliver energy produ...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of BlackRock MuniYield Pennsylvania Quality Fund and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 November 2025 in which we reassessed the appropriateness o...
Kalaris Reports Third Quarter 2025 Financial Results and Provides Busi...
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026 Recent significant corporate milestones include the selection of a CDMO, CFO hire, and opening of corporate headquarters Cash, cash equivalents and short-term investments of $77.0M as of September 30, 2025, expected to...
ONEOK to Participate in Investor Conference
ONEOK to Participate in Investor Conference TULSA, Okla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ONEOK, Inc. (NYSE: OKE) will participate in an investor conference this week and in a fireside chat session at 1:10 p.m. Eastern Time (12:10 p.m. Central Time) on Wednesday, Nov. 12. The session will be webcast live on ONEOK’s website at . The webcast will also be available for replay. ONEOK’s latest investor materials are available at . ------------------------------------------------------------------------------------------------------------------- At ONEOK (NYSE: OKE), we deliver energy p...
Occidental Announces Third Quarter 2025 Results
Occidental Announces Third Quarter 2025 Results HOUSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced its third quarter 2025 financial results. The earnings release and accompanying financial schedules can be accessed via the section of the company’s website at . The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Tuesday, November 11, 2025, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (internati...
Occidental Announces Dividend
Occidental Announces Dividend HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) announced today that its Board of Directors declared a regular quarterly dividend of $0.24 per share on common stock, payable on January 15, 2026, to stockholders of record as of the close of business on December 10, 2025. About Occidental is an international energy company with assets primarily in the United States, the Middle East and North Africa. We are one of the largest in the U.S., including a leading producer in the Permian and DJ basins, and offshore Gulf of America. Our provides flow assur...
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief...
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer Highly experienced biopharma financial officer joins leadership team CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in treatment naïve nAMD patients PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew Gall, MB...
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
Kalaris to Present at Stifel 2025 Annual Healthcare Conference PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference. Details: Type: Company presentationSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Thursday, November 13, 2025Time: 3:20 – 3:50pm ET...
ONEOK Declares Quarterly Dividend
ONEOK Declares Quarterly Dividend TULSA, Okla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- The board of directors of ONEOK, Inc. (NYSE: OKE) today declared a quarterly dividend of $1.03 per share, unchanged from the previous quarter, resulting in an annualized dividend of $4.12 per share. The dividend is payable Nov. 14, 2025, to shareholders of record at the close of business Nov. 3, 2025. ------------------------------------------------------------------------------------------------------------- At ONEOK (NYSE: OKE), we deliver energy products and services vital to an advancing world. W...
Occidental to Announce Third Quarter Results Monday, November 10, 2025...
Occidental to Announce Third Quarter Results Monday, November 10, 2025; Hold Conference Call Tuesday, November 11, 2025 HOUSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) will announce its third quarter 2025 financial results after close of market on Monday, November 10, 2025, and will hold a conference call to discuss the results on Tuesday, November 11, 2025, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at Participants may pre-register for the conference call at . Third...
ONEOK Third Quarter 2025 Conference Call and Webcast Scheduled
ONEOK Third Quarter 2025 Conference Call and Webcast Scheduled TULSA, Okla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- ONEOK, Inc. (NYSE: OKE) will release third quarter 2025 earnings after the market closes on Oct. 28, 2025. Members of ONEOK’s management team will participate in a conference call the following day. What: ONEOK third quarter 2025 earnings conference call and webcast When: 11 a.m. Eastern, Oct. 29, 202510 a.m. Central Where: 1) Phone conference call dial 800-343-4136, conference ID: OKE3Q25 2) Log on to the webcast...
Moody's Ratings says Occidental Petroleum's sale of OxyChem is credit ...
Moody's Ratings (Moody's) said that Occidental Petroleum Corporation's (OXY, Baa3 stable) ratings and outlook are not affected by the sale of its chemical business (OxyChem). The sale is credit positive, with the planned debt reduction, lower leverage and improved credit metrics more than offsetting...
Occidental Promotes Richard A. Jackson to Senior Vice President and Ch...
Occidental Promotes Richard A. Jackson to Senior Vice President and Chief Operating Officer HOUSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) announced today that its Board of Directors has promoted Richard A. Jackson to Senior Vice President and Chief Operating Officer, overseeing global oil and gas operations, low-carbon integrated technologies and the midstream and marketing and health, safety and environment functions. He will continue reporting to Vicki Hollub, President and Chief Executive Officer. Jackson was named Senior Vice President and President, U.S. Onshore Resources a...
ONEOK to Participate in Investor Conference
ONEOK to Participate in Investor Conference TULSA, Okla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- ONEOK, Inc. (NYSE: OKE) will participate in an investor conference this week and in a fireside chat session at 1:25 p.m. Eastern Time (12:25 p.m. Central Time) on Tuesday, Sept. 30. The session will be webcast live on ONEOK’s website at . The webcast will also be available for replay. ONEOK’s latest investor materials are available at . Analyst Contact: Megan Patterson ONEOK, Inc. 918-561-5325 Media Contact: Alicia Buffer ONEOK, Inc. 918-861-3749
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascend...
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kalari...
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose ...
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and preliminary efficacy in nAMD patients receiving up to four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWS...
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.